Daniel Hu, PharmD, BCCCP is a critical care and emergency medicine pharmacist who completed a fellowship in academia and research with the U.S. Food and Drug Administration’s Office of Minority Health and Health Equity (OMHHE) and University of Hawaii at Hilo Daniel K. Inouye College of Pharmacy (DKICP), followed by an acute care residency at Providence St. Peter Hospital in Olympia, WA. Since then, Dan has worked in multiple hospitals as a pharmacist specializing in critical care and emergency medicine. He has taught at the University of Hawaii at Hilo, Pacific University, and Washington State University, where he received a teaching certificate and currently holds an adjunct faculty position. Dan is a frequent speaker at local and national conferences and has multiple publications on topics in healthcare. He continues to be actively involved in research and academia and serves on the editorial board for the Hawaii Journal of Health & Social Welfare.

Wang

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Wang Y. Lancet; Epub Ahead of Print. doi: https://doi.org/10.1016/S0140-6736(20)31022-9 Clinical Question In patients with severe COVID-19, does intravenous remdesivir, compared with placebo, improve the time to clinical improvement? Background Despite the ongoing research efforts to find a treatment for patients infected with SARS-CoV-2, there are currently no proven […]

Continue reading »